A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
Status:
Not yet recruiting
Trial end date:
2023-09-29
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of
DS-1211b, and pharmacokinetics (PK) in individuals with Pseudoxanthoma elasticum (PXE). PXE
is a rare disease that is associated with significant risks of visual impairments and
comorbidity from peripheral and cardiovascular diseases, and adversely impacts the quality of
life in afflicted individuals.